Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
Crossref DOI link: https://doi.org/10.1007/s40261-016-0422-y
Published Online: 2016-06-28
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Groenendaal-van de Meent, Dorien
Adel, Martin den
Noukens, Jan
Rijnders, Sanne
Krebs-Brown, Axel
Mateva, Lyudmila
Alexiev, Assen
Schaddelee, Marloes
Funding for this research was provided by:
Astellas Pharma Europe
License valid from 2016-06-28